The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The therapeutic proteins market has seen remarkable growth in recent years, driven by technological innovations and expanding applications in medicine. This blog delves into the current state and future projections of this dynamic market, highlighting key trends, technological advancements, and the major players shaping its future.

Market Growth Overview

Rapid Market Expansion

• 2023 Market Size: $140.96 billion
• 2024 Projected Market Size: $158.16 billion
• CAGR (2023-2024): 12.2%

The market’s rapid growth is attributed to several factors:

• Advances in protein engineering
• Expansion into treatments for chronic diseases
• The advent of immunotherapy
• Development of recombinant DNA technology
• Targeted cancer therapies

Future Market Projections

• 2028 Projected Market Size: $257.4 billion
• CAGR (2024-2028): 12.9%

Future growth will be driven by:

• Regulatory adaptations
• Enhanced delivery systems
• Integration of gene editing
• Development of biobetters
• Evolution of immunotherapy

View More On The Therapeutic Proteins Market Report 2024 – https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Technological Advancements Fueling Growth

Role of Protein Engineering

Technological advancements are a key driver of the therapeutic proteins market:

• Protein-Engineering Technologies: Glycoengineering, pegylation, Fc-fusion, albumin fusion, and albumin drug conjugation
• Benefits: Increased production yield, product purity, circulating half-life, targeting, and functionality

Key FDA-Approved Therapeutic Proteins

Recent FDA-approved therapeutic proteins developed using advanced technologies include:

• Belimumab
• Ipilimumab
• Taliglucerase alfa
• Albiglutide
• Recombinant human coagulation factor IX

Major Companies in the Market

Prominent players in the therapeutic proteins market include:

• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co. Inc.
• AbbVie Inc.
• Novartis International AG
• Sanofi S.A.
• Bristol Myers Squibb Co.
• AstraZeneca PLC
• Abbott Laboratories
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• Amgen Inc.

Expanding Production Capacities with Media Systems

Media Systems for Production

To meet the growing demand for therapeutic proteins, companies are introducing innovative media systems:

• Lonza Group AG’s TheraPRO CHO Media System: Launched in July 2023, this new cell culture platform enhances productivity and quality in therapeutic protein manufacturing. It features:
  • Simple, two-part chemically specified production technique
  • Full scalability
  • Support from technical professionals with extensive troubleshooting expertise

Market Segmentation

The therapeutic proteins market is segmented by:

• Product Type: Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone
• Function: Enzymatic and Regulatory Activity, Special Targeting Activity, Vaccines, Protein Diagnostics
• Application: Metabolic Disorders, Immunologic Disorders, Hematological Disorders, Cancer, Hormonal Disorders, Genetic Disorders, Other Applications

Regional Insights

• North America: The largest region in the therapeutic proteins market in 2023

Conclusion

The therapeutic proteins market is poised for significant growth, driven by technological advancements, regulatory changes, and evolving therapeutic needs. With major companies investing in innovative production systems and expanding their capabilities, the future looks promising for this dynamic sector. As personalized medicine and biotechnology continue to evolve, therapeutic proteins will play an increasingly vital role in modern healthcare.

Request A Sample Of The Global Therapeutic Proteins Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=2555&type=smp